Cytosorbents Corp
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
CTSO$5.80-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year ended · · Year ended · · Year ended | |||||||||
| · · December 31, · · December 31, · · December 31, | |||||||||
| · 2023 · · 2022 · · 2021 | |||||||||
| Revenue: · · · | |||||||||
| CytoSorb sales | | $31,015,268 | | $28,572,709 | | $39,996,700 | |||
| Other sales | | | 69,685 | | | 787,201 | | | 111,867 |
| Total product sales | | | 31,084,953 | | | 29,359,910 | | | 40,108,567 |
| Grant income | | | 5,264,426 | | | 5,328,899 | | | 3,056,960 |
| Total revenue | | | 36,349,379 | | | 34,688,809 | | | 43,165,527 |
| Cost of revenue | | | 13,957,356 | | | 13,955,752 | | | 11,047,350 |
| Gross profit | | | 22,392,023 | | | 20,733,057 | | | 32,118,177 |
| Operating expenses: | | | | | | ||||
| Research and development | | | 15,728,915 | | | 15,118,907 | | | 16,380,930 |
| Legal, financial and other consulting | | | 4,272,296 | | | 2,847,899 | | | 2,731,515 |
| Selling, general and administrative | | | 33,600,065 | | | 34,288,130 | | | 35,750,477 |
| Total operating expenses | | | 53,601,276 | | | 52,254,936 | | | 54,862,922 |
| Loss from operations | | | (31,209,253) | | | (31,521,879) | | | (22,744,745) |
| Other income (expense): | | | | | | | |||
| Interest income (expense), net | | | (157,891) | | | 132,597 | | | 28,007 |
| Gain (loss) on foreign currency transactions | | | 1,949,257 | | | (2,448,583) | | | (2,577,913) |
| Miscellaneous income (expense) | | | 96,754 | | | (67,303) | | | — |
| Total other income (expense), net | | | 1,888,120 | | | (2,383,289) | | | (2,549,906) |
| | | | | | | ||||
| Loss before benefit from income taxes | | | (29,321,133) | | | (33,905,168) | | | (25,294,651) |
| | | | | | | | | | |
| Benefit from income taxes | | 813,739 | | 1,092,585 | | 736,003 | |||
| | | | | | | ||||
| Net loss attributable to common stockholders | | $(28,507,394) | | $(32,812,583) | | $(24,558,648) | |||
| | | | | | | | | | |
| Basic and diluted net loss per common share | | $(0.64) | | $(0.75) | | $(0.57) | |||
| | | | | | | | | | |
| Weighted average number of shares of common stock outstanding | | | 44,656,391 | | | 43,573,215 | | | 43,359,186 |
| | | | | | | | | | |
| Comprehensive loss: | | | | | | | | | |
| Net loss | | $(28,507,394) | | $(32,812,583) | | $(24,558,648) | |||
| Other comprehensive income (loss): | | | | | | | | ||
| Foreign currency translation adjustment | | | (1,799,874) | | | 1,803,610 | | | 2,259,663 |
| Comprehensive loss | | $(30,307,268) | | $(31,008,973) | | $(22,298,985) | |||
CONSOLIDATED STATEMENTS OF CHANGES IN
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.